DIFFERENTIAL SARS-COV-2 ANTIGEN SPECIFICITY OF THE HUMORAL RESPONSE IN INACTIVATED VIRUS-VACCINATED, CONVALESCENT, AND BREAKTHROUGH SUBJECTS

- 4 Luisa F. Duarte^{1#}, Yaneisi Vázquez^{1#}, Benjamín Diethelm-Varela^{1#}, Valentina Pavez¹,
- 5 Roslye Berríos-Rojas¹, Jessica A. White², Alexis M. Kalergis^{1,3}, Susan M. Bueno¹ and Pablo

6 A. González^{1*}

7

- ¹Millennium Institute on Immunology and Immunotherapy, Departamento de Genética
 Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica
- 10 de Chile, Santiago, Chile.
- ¹¹ ²PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA
- 12 ³Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de
- 13 Chile, Santiago, Chile.
- 14 [#]Equal contribution.
- 15 *Correspondence to: pagonzalez@bio.puc.cl
- 16
- Keywords: Inactivated Vaccine, CoronaVac, SARS-CoV-2, antigens, differential diagnosis,
 biomarkers

Abbreviations: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2); The
etiological agent of coronavirus disease 2019 (COVID-19); World Health Organization
(WHO); Geometric mean titer (GMT); Receiver operating characteristic (ROC); Polymerase
chain reaction (PCR); Optical density (OD); Binding antibody units (BAU); Area under the
curve (AUC).

25 ABSTRACT

26 Analytical methods for the differential determination between natural infection with SARS-27 CoV-2 vs. immunity elicited by vaccination or infection after immunization (breakthrough 28 cases) represent attractive new research venues in the context of the ongoing COVID-19 29 pandemic caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). 30 Herein, we set out to compare humoral responses against several SARS-CoV-2 structural and 31 non-structural proteins in infected unvaccinated (convalescent), vaccinated, as well as 32 vaccinated and infected (breakthrough) individuals. Our results indicate that immunization 33 with an inactivated SARS-CoV-2 vaccine (CoronaVac) induces significantly higher levels 34 of IgG antibodies against the membrane (M) protein of SARS-CoV-2 as compared to 35 convalescent subjects both, after the primary vaccination schedule and after a booster dose. 36 Moreover, we found that CoronaVac-immunized individuals, after receiving a third vaccine 37 shot, display equivalent levels of N-specific IgG antibodies as convalescents subjects. 38 Regarding non-structural viral proteins, for the two viral proteins ORF3a and NSP8, IgG 39 antibodies were produced in more than 50% of the convalescent subjects. Finally, a logistic 40 regression model and a receiver operating characteristic (ROC) analysis show that combined 41 detection of M and N proteins may be useful as a biomarker to differentiate breakthrough 42 cases from vaccinated and convalescent individuals that did not receive prior vaccination. 43 Taken together, these results suggest that multiple SARS-CoV-2 antigens may be used as 44 differential biomarkers for distinguishing natural infection from vaccination.

45 **1. INTRODUCTION**

46 Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), the etiological 47 agent of coronavirus disease 2019 (COVID-19), produces significant morbidity and mortality 48 worldwide that has caused significant strain on public health systems, altogether imposing 49 severe social and economic burdens to nations around the globe [1,2]. Starting the year 2021, 50 most countries worldwide have deployed massive vaccination campaigns that successfully 51 curb the worst outcomes of COVID-19. However, the immune responses elicited in 52 convalescent individuals, the vaccinated, and those vaccinated and infected (breakthrough) 53 cases remain to be studied in depth in the upcoming years in such a way to identify and better 54 understand potential correlates of protection against infection with this virus [3]. Worldwide, 55 more than a dozen vaccines have been approved by the World Health Organization (WHO), 56 which are based on different technological platforms, compositions and administration 57 schedules [4,5]. Importantly, whole inactivated SARS-CoV-2 vaccines account for nearly 58 half of the total number of doses administrated in the world population, and CoronaVac 59 (Sinovac Biotech) has been approved in over 30 countries within mass vaccination 60 campaigns in low and middle-income countries [6], with favorable safety and 61 immunogenicity results [7–10]. The efficacy and effectiveness of this vaccine against 62 COVID-19-related hospitalizations and deaths are significant [11–16], especially when 63 immunity is reinforced with a booster dose [17–20].

Whole-virus vaccines have a variety of structural viral antigens, many of which are not present in mRNA- or vector-based vaccines [7]. Importantly, whole-virus vaccines may elicit, to some extent, immune responses that mimic natural infection with SARS-CoV-2. However, because the profile of antigenic proteins presented in the context of infectious virus and contained in the inactivated viral particles within the vaccine are not identical, we

69 hypothesized that natural infection versus inactivated-virus vaccination or breakthrough 70 cases elicits differential humoral responses against SARS-CoV-2 proteins. Thus, we sought 71 to identify these putative differences, which could eventually be used as biomarkers for the 72 differential serodiagnosis of individuals naturally infected with SARS-CoV-2 versus those 73 immunized with inactivated-virus vaccine or breakthrough cases undergoing infection after 74 vaccination.

75 The SARS-CoV-2 genome encodes four structural proteins, namely Spike (S), 76 nucleocapsid (N), membrane (M), and envelope (E), and 16 non-structural proteins (NSP1-77 NSP16), along with several accessory proteins (ORF3a, 3d, 6, 7a, 7b, 8, 9b, 14, and 10) that 78 play key roles in immune evasion and the replication cycle of the virus [21,22]. Among these 79 proteins, the viral structural protein S is highly immunogenic, and the induction of binding-80 and neutralizing anti-S antibodies by vaccines against SARS-CoV-2 have been the focus of 81 extensive investigation during the last two years [23–27]. However, antibodies against other 82 SARS-CoV-2 proteins, such as those produced against virus-inactivated vaccines, are less 83 known and thus, require further characterization for a better understanding of the kinetics 84 and extent of the host immune profiles generated against this virus and potentially identifying 85 correlates of protection.

In this study, we compared the humoral immune responses elicited against the N, M, and E-structural proteins of SARS-CoV-2, as well as the non-structural ORF3a, and NSP8 proteins of this virus among unvaccinated convalescent individuals that survived SARS-CoV-2 infection, and subjects immunized with the SARS-CoV-2-inactivated CoronaVac vaccine at different stages during their vaccination and booster schedule. We also analyzed and compared this humoral response in CoronaVac-vaccinated individuals later infected with SARS-CoV-2 (breakthrough cases) [17]. Overall, our data show that anti-N IgG antibodies

93	are produced significantly in the vaccinated group only after administering a booster dose of
94	CoronaVac, and anti-M IgG antibody titers were higher in the vaccinated group as compared
95	to convalescent individuals. Conversely, convalescent individuals displayed high titers of
96	anti-N antibodies, which remained elevated for at least eight weeks after recovery from
97	SARS-CoV-2 infection. These individuals also displayed a seropositivity rate above 50% for
98	the NSP8 protein. Regarding breakthrough cases, an antibody pattern characteristic of an
99	anamnestic immune response was elicited, resulting in a substantial boost of titers against
100	surface antigens within the virus. Finally, we performed a receiver operating characteristic
101	(ROC) analysis to differentiate breakthrough cases between vaccinated volunteers and
102	convalescent individuals without previous vaccination. Importantly, we found at the protein
103	level that the antibody responses against the combination of the N and M viral proteins may
104	serve to discriminate between these individuals with an appropriate cutoff criterion.

105 2. MATERIALS AND METHODS

106 **2.1 Subjects**

107 Serum samples from subjects between 18 to 59 years and older than 60 years 108 belonging to the CoronaVac03CL Phase 3 scientific-clinic study carried out in Chile were 109 obtained from the following groups: i) pre-immune: sera obtained at the moment of the first 110 dose, ii) second dose + 2 weeks: sera obtained from subjects vaccinated with the second dose 111 of CoronaVac (28 days post-first dose) plus two weeks, iii) second dose + 4w: sera from subjects vaccinated with the second dose of CoronaVac plus four weeks, iv) third dose + 4w: 112 113 sera from subjects vaccinated with the booster dose of CoronaVac (6 months after the first 114 dose) plus four weeks, vi) breakthrough + 2w: serum obtained from subjects vaccinated with 115 two doses of CoronaVac and then naturally infected with SARS-CoV-2, from whom the 116 samples were taken two weeks after a positive polymerase chain reaction (PCR) test, and vii) breakthrough + 4w: serum from subjects vaccinated with two doses of CoronaVac and 117 118 infected with SARS-CoV-2, from whom the sample was taken four weeks after a positive 119 PCR test. At least 25 subjects were evaluated for the vaccinated group and 10 for the 120 breakthrough cases. Sera obtained from the biobank of clinical samples within the PATH 121 institution was grouped as follows: i) naive: sera from 10 subjects who were not exposed to 122 the virus and were taken before the year 2020, ii) convalescents: sera from 9 subjects who 123 were infected with SARS-CoV-2 and then blood samples were taken for serum recollection 124 at 1, 2, 4 and 8 weeks after symptom-onset, iii) 10 samples obtained from convalescent 125 subjects that were classified with low, mid and high titer against SARS-CoV-2, but the time 126 of the sample collection was not detailed (unspecified). The age of these subjects was 127 unknown. Table 1 summarizes the description of all samples included in this study. Blood 128 samples were obtained from volunteers recruited in the clinical trial CoronaVac03CL

(clinicaltrials.gov #NCT04651790) carried out in Chile starting in November 2020. The
study was approved by the sponsoring institution Ethical Committee (ID 200708006), each
Institutional Ethical Committee of the other sites, and the Public Health Institute of Chile
(ISP Chile, number 24204/20). Execution of the trials was conducted according to the current
Tripartite Guidelines for Good Clinical Practices, the Declaration of Helsinki and local
regulations.

135 **2.2 Dot blot**

136 To immobilize recombinant proteins on a solid matrix, 500 ng of each protein was 137 diluted in 20 mM phosphate buffer (mixture of monobasic and dibasic phosphate), 0.5 M 138 NaCl, and 8 M urea were spotted onto a nitrocellulose membrane (in 2 uL volume) (Thermo 139 Scientific). Membranes with spots were air-dried for 15 min and subsequently blocked with 140 10% BSA diluted in 0.05% Tween-20 in PBS, for 2 h at RT. After incubation, the membranes 141 were washed with 0.05% Tween-20 in PBS (twice). Next, the membranes were incubated 142 overnight at 4°C with a sera pool from naive, convalescents (+ 4 weeks), vaccinated with 143 second dose + 2 weeks, and breakthrough (PCR(+) + 2 weeks) subjects. A sera pool was 144 incubated in a dilution of 1/250 with 1% BSA diluted in 0.05% Tween-20 in PBS. As positive 145 control, all proteins (500 ng) were incubated with an anti-His Tag antibody conjugated with 146 biotin at a dilution of 1:3,000 in 1% BSA diluted in 0.05% Tween-20 in PBS (Supplementary 147 Figure 1). After incubation, the membranes were washed with 0.05% Tween-20 in PBS (three 148 times x 5 min) and incubated for 1 h at RT with 1:2,000 anti-human IgG-HRP (1 mg/ml, BD) 149 diluted in 1% BSA with 0.05% and Tween-20 in PBS. The membranes with an anti-His Tag-150 biotin antibody (Genscript, # A00613) were incubated with Streptavidin-HRP (1:6,000; 151 Abcam #7403). Finally, membranes were washed with 0.05% Tween-20 in PBS (three 152 times), once with PBS, and then incubated with an enhanced chemiluminescence Western

blot detection system (Femto, ECL, Thermo Scientific # 34094). Proteins evaluated included
ORF1a polyprotein (Invitrogen, #RP-87701), ORF3a (LSBio, #LS-G145920), ORF8
(LSBio, #LS-G145919), NSP1 (R&D systems, #10666-CV), NSP8 (R&D systems, #10633CV), NSP9 (R&D systems, #10631-CV), NSP10 (R&D systems, #10630-CV), NSP14 (R&D
systems, #10667-CV), E (Sino Biological, #40609-V10E3) and ME (Sino Biological,
#40598-V07E).

159 2.3 ELISA assays

160 In-house indirect ELISA assays were performed to detect humoral immunity against 161 N-SARS-CoV-2 (R&D systems, #10474-CV), M (R&D systems, #10690-CV), E (Sino 162 Biological, #40609-V10E3), ORF3a (LSBio, #LS-G145920) and NSP8 (R&D systems, 163 #10633-CV). Briefly, high-binding 96-well ELISA plates (Corning, #9018) were activated 164 with 100 ng of N and M antigen dissolved in carbonate-bicarbonate buffer (Bioleged 1x, 165 #421701) for 1 h at 37°C and blocked with 10% m/w milk in PBS 1X - Tween 20 (0.05%) 166 overnight at 4°C. Denaturing buffer (20 mM monobasic and dibasic phosphate buffer, 0.5 167 NaCl, and 8 M urea) was used as co-acting buffer to evaluate anti-ORF3a, anti-E, and anti-168 NSP8-SARS-CoV-2 (250 ng, 500 ng and 200 ng, respectively). Afterward, the plates were 169 incubated with sera from participants using serial dilution factors ranging from 1/250 to 170 1/16,000 (N and M) and 1/50 to 1/1,600 (E, NSP8, and ORF-3a proteins) for 1 h at 37°C 171 (diluted 1% m/w milk in PBS 1X - Tween 20 (0.05%)). In parallel, a WHO standard curve 172 (NIBSC code: 20/268) was performed from dilutions of 1/40 to 1/360. Then, the plates were 173 incubated with anti-human IgG-HRP (BD, # 555788) for 30 min at room temperature in 174 darkness. Finally, plates were resolved using commercial TMB (BD OptEIA, # 555214), 175 consisting of a substrate mixture, which was incubated at room temperature for 15 min in

darkness. This reaction was stopped using 2N H₂SO₄, and the absorbance at 450 nm was
read.

178 **2.4 Data analysis**

179 For all ELISA assays, corrected optical density (OD) values were calculated by 180 obtaining the average between each subject's two replicates and subtracting the 181 corresponding subject's blank (i.e., the OD measurement from the "inactivated" well) for 182 each dilution factor. An absorbance cutoff was calculated for each dilution factor to establish 183 the seropositivity threshold. For each subject, the antibody titer was defined as the highest 184 dilution factor where the corrected OD was higher than the cutoff value for the corresponding 185 dilution factor. Geometric Mean of Titers (GMTs) was calculated using all subject titers for 186 a given visit. A standard curve was used to plot the antibody responses against the M, N, and NSP8 proteins in the samples as binding arbitrary units (BAU), by using the WHO 187 188 International Standard for SARS-CoV-2 antibody (NIBSC code: 20/268), which was 189 prepared according to the manufacturer's instructions [28]. Data were analyzed using the log 190 concentration transformed, and the final concentration for each sample was the average of 191 the product of the interpolated BAU from the standard curve and the sample dilution factor 192 required to achieve the OD450 value that fell within the linear quantitative range. Samples 193 with undetermined concentrations at the lowest dilution tested were assigned the lower limit 194 of quantification (28.6; 23.6; and 13.5 BAU for N, M, and NSP8, respectively).

195 Statistical differences in GMT values among all the different evaluated times and 196 proteins by group were assessed using a two-way analysis of variance (ANOVA) with 197 Tukey's multiple comparison test. Comparisons between CoronaVac-vaccinated individuals 198 and convalescents subjects were assessed using the Kruskal-Wallis test with Dunn's multiple

- 199 comparisons test. The significance threshold was set at $\alpha = 0.05$. GraphPad Prism 9.0 was
- 200 used for data plotting, multiple logistic regression, and ROC curve statistical analyses.

202 **RESULTS**

203 Kinetics and extent of SARS-CoV-2-specific antibodies responses in convalescents, 204 CoronaVac-vaccinated individuals, and breakthrough cases.

205 To assess which are those antigens that contribute to the humoral response elicited 206 after natural infection, vaccination, or infection after vaccination (breakthrough cases), first 207 we performed dot blot analyses using a subset of non-structural (ORF1a, ORF3a, ORF8, 208 NSP1, NSP8, NSP9, NSP10, NSP14,) and structural (E and M) recombinant viral proteins 209 with serum pools from COVID-19 convalescent patients, CoronaVac-vaccinated individuals, 210 and breakthrough cases. Naïve individuals were also included as controls. In these 211 experiments, we detected some degree of differential immunoreactivity between the 212 evaluated groups, mainly for the M and E structural proteins and the non-structural proteins 213 ORF3a and NSP8 (Supplementary Figure 1). We then evaluated the kinetics of the specific-214 IgG antibodies for these proteins and the structural N protein by ELISA in convalescent 215 individuals, subjects vaccinated with two or three doses of CoronaVac, and breakthrough 216 cases. Subject data and sampling times are detailed in Table 1.

217 As expected, CoronaVac-vaccinated individuals showed a humoral immune response 218 that was polarized towards structural components within the virion (Figure 1A-C). 219 Remarkably, N-specific IgG antibody titers were significantly elevated only four weeks after 220 administering the third dose, compared to naïve controls, pre-immune samples, and sera 221 obtained two weeks after the second dose. Conversely, M-specific antibodies titers showed 222 a significant increase four weeks after the second dose, similar to those obtained after the 223 booster dose (Figure 1A). There were no significant differences between vaccinated 224 individuals and the negative controls for the NSP8 and ORF3a antigens (Figure 1B). The

highest response in the vaccinated group was elicited against the N protein after the booster dose, which reached 87% seropositivity. In contrast, only around 50% of the individuals had N-specific antibodies after the second dose or M-specific antibodies after two or three doses of the vaccine. On the other hand, approximately 20% of the vaccinated individuals displayed a response against the NSP8 protein (Figure 1C).

230 Regarding the convalescent individuals, we detected significant differences in 231 antibody titers between patients and naïve controls when assessing reactivity towards the N-232 structural protein and the NSP8-non-structural protein (Figure 1D-F). Sequential samples 233 from some individuals showed that the antibody response against the N protein was 234 significantly higher compared to naïve individuals starting two weeks after the onset of the 235 symptoms and was maintained for up to eight weeks (Figure 1D). Moreover, we observed 236 that the earliest antibody response in the convalescent group was elicited for the NSP8 protein 237 after one and two weeks from the symptom's onset (Figure 1E). The most immunogenic 238 protein in this group was the N protein, with seropositivity rates ranging from 78 to 89% at 239 two and four weeks after symptoms onset, respectively, followed by NSP8, which showed a 240 seropositivity rate of 70 and 63% after one or two weeks, respectively (Figure 1F).

We next investigated the specific-IgG antibody responses produced in individuals with symptomatic SARS-CoV-2 infection who were previously vaccinated with two doses of CoronaVac (breakthrough cases) (Figure 1G-I). In this case, the N-specific IgG antibodies showed the highest levels at both times evaluated, two and four weeks after COVID-19 diagnosis, and showed 100% seropositivity rates. Although the antibody titers for the M protein did not reach significant levels as compared to naïve controls, they showed high seropositivity rates within 100 and 89% at two and four weeks after COVID-19 diagnosis,

respectively (Figures 1G and I). To a lesser extent, we also found a significant difference at the antibody level between breakthrough cases and naïve controls for the NSP8 after two weeks, with a seropositivity rate of 40% (Figures 1H and I).

To harmonize the assessment of the humoral immune response after natural infection, vaccination, or in breakthrough cases, the WHO has recommended reporting the binding activity results in binding antibody units (BAU), using the first international standard (IS) for anti-SARS-CoV-2 immunoglobulin [29–31]. Antibody titers were obtained for the M, N, and NSP8 proteins as BAU (**Supplementary Figure 2 and Supplementary Table 1**). Antibody values for other viral proteins could not be reported as BAU, due to the low level of detection.

Overall, our results show that CoronaVac induces a broad humoral immune response, including high levels of N- and M-specific antibodies in an important percentage of vaccinated individuals, which was enhanced after natural infection in breakthrough cases. On the other hand, convalescent individuals who had not been vaccinated before infection developed a modest but statistically significant increase in antibody response against nonstructural components of the virion.

264

265 SARS-CoV-2-IgG responses among CoronaVac-vaccinated individuals, COVID-19 266 convalescent, and breakthrough subjects

To further investigate differences in the antibody responses between CoronaVacvaccinated individuals and COVID-19 convalescent subjects, we analyzed the geometric mean titers (GMTs) elicited in each group, those vaccinated with two or three doses of

CoronaVac, breakthrough cases after two doses of CoronaVac, and convalescent individuals without prior vaccination. Time-points evaluated were four weeks after the second or booster dose and four weeks after a positive PCR test for breakthrough cases. We also analyzed data from convalescent individuals that had sample collection with unspecified dates and samples from convalescent individuals whose samples were collected four weeks after symptom onset. A summary of the GMT values and seropositivity rate obtained at these time points are shown in Table 2.

277 Interestingly, the antibody responses were highest among breakthrough cases for the 278 structural proteins N and M. As shown in Figure 2, significant differences of 11 and 18-fold 279 were observed in terms of the magnitude of the anti-N and anti-M-specific IgG responses 280 between breakthrough cases and convalescent individuals (GMTs: 11313.7 vs. 1000 and 281 2939.5 vs. 161.4, respectively). Importantly, convalescent individuals also had binding anti-282 M-specific IgG titers that were 4-fold lower than vaccinated individuals that received two or 283 three vaccine doses, which reached similar GMTs of 688.5 and 643.3, respectively (Figures 284 **2A and B).** We observed no significant difference in the overall levels of the anti-E-specific 285 antibody responses in vaccinated individuals compared to convalescents, suggesting that 286 infection or vaccination alone does not induce significant antibody responses against this 287 protein (Figure 2C).

Regarding the non-structural proteins evaluated, no differences were observed for the NSP8 protein, as some vaccinated individuals displayed high titers against this protein, and all groups reached GMTs of 92.3 and 87.1 after two or three vaccine doses, respectively. Likewise, breakthrough cases reached a GMT of 107.2 and the convalescent group a GMT of 149.4 (Figure 2D). These results suggest that vaccinated individuals may have had prior

exposure to other coronaviruses that elicit cross-reactivity, displaying a nonspecific antibody immune response against this protein. However, this response was not boosted after natural exposure to SARS-CoV-2. By contrast, we detected significantly higher ORF3a-specific antibody titers in convalescent individuals than in CoronaVac-vaccinated subjects (GMT: 44.5 vs. 25 and 27.5 for two or three vaccine doses, respectively) (Figure 2E).

298 Finally, we performed a receiver operating characteristic (ROC) analysis to identify 299 which of the evaluated SARS-CoV-2 proteins may better differentiate CoronaVac-300 vaccinated from convalescent individuals. Using this approach, the best performance was 301 obtained when testing structural proteins but depended on the number of doses administered 302 to the subjects. On the one hand, high area under the curve (AUC) values were obtained for 303 the N (0.72; 95%CI:0.56-0.88) and the M proteins (0.69; 95%CI:0.54-0.85) when comparing 304 vaccinated individuals with CoronaVac-vaccinated individuals receiving only two doses and 305 convalescents (Figure 2F). On the other hand, the N protein showed a low AUC value (0.55; 306 95%CI:0.38-0.72) when comparing vaccinated individuals receiving the third dose with 307 convalescents, and in this case, on the contrary, the highest AUC value was achieved for the 308 M protein (0.73; 95%CI:0.57-0.88) (Figure 2G).

In summary, these results show that vaccinated individuals have a broader immune response and higher antibody titers against structural components of SARS-CoV-2 compared to individuals who underwent a natural infection without prior vaccination.

312

313 Combination of N- and M-specific antibody responses for differentiating breakthrough
314 cases from vaccinated-only, and convalescents individuals.

As inactivated vaccines elicit a broad humoral immune response against various antigens, the serological diagnosis of previously vaccinated individuals and the evaluation of vaccine efficacy in a virus-exposed population is challenging. Next, we performed ROC analyses to identify SARS-CoV-2 proteins that may differentiate the antibody responses elicited in breakthrough cases from vaccinated-only individuals and convalescents subjects.

320 As shown in **Figure 3A**, when the humoral immune response elicited in breakthrough 321 cases is compared with that elicited by individuals vaccinated with two doses of CoronaVac, 322 we found AUC values of 0.92 (95%CI:0.83-1.0, N), 0.71 (95%CI:0.54-0.89, M), 0.55 323 (95%CI:0.35-0.75, E), 0.52 (95%CI:0.30-0.74, NSP8), and 0.55 (95%CI:0.33-0.77, ORF3a) 324 for each protein, suggesting that M and N proteins could be useful for discriminating between 325 both groups. We further compared individuals who received a booster dose (third dose) and 326 found a similar tendency with the highest AUC values obtained for the N and M proteins, 327 0.83 (95%CI:0.68-0.97), and 0.76 (95%CI:0.58-0.94), respectively (Figure 3B). 328 Remarkably, these proteins are also able to differentiate infected subjects without prior 329 vaccination (convalescents) from breakthrough cases (vaccinated, then infected), with AUC 330 values up to 0.90 (95%CI:0.77-1.0), for the N protein and 0.93 (95%CI:0.81-1.0), for the M 331 protein (Figure 3C). In addition, we performed multiple logistic regression analyses to 332 evaluate the capacity of the combined detection of N- and M-specific IgG antibodies to 333 distinguish breakthrough cases from the other groups evaluated. As shown in Figures 3D-F, 334 the combined data improved the AUC values obtained to 0.95 (95%CI:0.88-1.0), 0.88 335 (95%CI:0.75-1.0), and 0.98 (95%CI:0.95-1.0), respectively. Importantly, this approach showed high negative and positive predictive powers of 92% and 80% for differentiating 336 337 breakthrough cases with vaccinated individuals that received two doses, and 90% and 73%

338	when compared with subjects vaccinated with the booster dose, and lastly, 90% and 89%
339	when comparing with convalescent individuals, suggesting this may be a valuable strategy
340	for serological diagnosis and vaccine efficacy evaluation. Moreover, scatter plots performed
341	with hypothetical cutoffs of IgG antibody titers showed that it is possible to cluster the
342	majority of the breakthrough cases in the quadrant with the highest values for N and M
343	antibody titers (Cutoff \geq 1,500 M or N-specific IgG antibody titters), as compared with
344	vaccinated-only individuals (two or three doses), or infected-only subjects (convalescents)
345	(Figures 3G-I).

Overall, these results suggest that the combination of N- and M-specific IgG antibody levels could be a reliable biomarker for detecting vaccinated individuals who have had a mild or asymptomatic SARS-CoV-2 infection and potentially differentiate infected individuals from those with mixed immunity resulting from infection and vaccination with CoronaVac.

350 **DISCUSSION**

351 In the context of the COVID-19 pandemic and mass vaccination campaigns being 352 deployed around the world, a better understanding of the humoral immune response arising 353 from either natural infection, vaccination, or infection after vaccination is highly relevant as 354 a potential diagnostic tool that may help better determine epidemiological surveying and 355 public health strategies. This may also help identify potential new correlates of protection 356 against SARS-CoV-2 [32,33]. For the vaccinated individuals, we analyzed the immune 357 response elicited against a widely used inactivated SARS-CoV-2 vaccine (CoronaVac, 358 Sinovac Biotech's), given its significant deployment worldwide with billions of doses 359 administered so far. Because this vaccine consists of whole inactivated SARS-CoV-2, it is 360 composed of a diverse set of structural antigens that could be presented to the immune 361 system, and thus it is somewhat expected to elicit a humoral immune response that may 362 mirror natural infection [34].

363 Interestingly, antibodies raised against SARS-CoV-2 antigens were elicited at 364 significantly different levels in individuals recovering from natural infection, after 365 immunization with CoronaVac, and breakthrough cases. Furthermore, we found that 366 antibody titers directed against the M-SARS-CoV-2 protein were significantly higher in the 367 case of vaccinated individuals, as opposed to natural infection in unvaccinated individuals. 368 Importantly, we observed high titers of anti-N antibodies in individuals boosted with an 369 additional dose of inactivated SARS-CoV-2 vaccine, equivalent to those observed in 370 convalescent individuals. Regarding breakthrough cases, we found a potent immune response 371 for the two structural proteins N and M, suggesting that these humoral responses could be 372 used to differentially detect immunity elicited after natural infection in this vaccinated group, 373 as opposed to non-vaccinated infected individuals. Although we did not analyze potential

374 correlations between the elicited antibody responses and protection against COVID-19, 375 previous reports suggest that hybrid immunity, or additional antigen exposure after natural 376 infection before or after vaccination, is associated with a lower risk of reinfection, as well as 377 reduced COVID-19 hospitalization when compared to naturally acquired immunity after 378 infection alone [35,36]. Interestingly, high levels of IgG against the N protein, at the time of 379 hospital admission, has been correlated with worsen COVID-19 clinical courses [37], which 380 could be attributed to increased IL-6 production mediated by N-specific IgG antibodies 381 observed after COVID-19 cytokine storm [38]. On the contrary, high levels of IgG against 382 the N protein, detected after COVID-19 recovery, have been associated with a long-term 383 protective effect against re-infections [39]. The effect of other antibodies on the outcome of 384 COVID-19 has not been explored to date.

385 On the other hand, antibody titers against the ORF3a protein seemed to be elicited 386 almost exclusively in response to natural infection in non-vaccinated individuals 387 (convalescents) [40,41]. Therefore, ORF3a-SARS-CoV-2 may represent a biomarker to 388 differentiate natural SARS-CoV-2 infection from vaccination. Noteworthy, only a fraction 389 (50%) of the infected individuals responded to this antigen, which should be considered for 390 further analyses. Furthermore, NSP8-specific antibodies were elicited in a great percentage 391 of convalescent individuals at early time points (70% during the first week after symptom 392 onset). Although some individuals in the vaccinated group responded to this antigen, it is 393 unclear whether they were previously exposed to the virus before vaccination or whether it 394 corresponds to potential antibody cross-reactivity against other coronaviruses. However, 395 these findings need to be corroborated in future larger-scale studies to confirm the diagnostic 396 value of this protein and its potential use as a biomarker for SARS-CoV-2 infection.

397 Importantly, as discussed in the preceding paragraph, our results show that 398 immunization with CoronaVac, namely three doses, robustly elicits antibodies against the N 399 and M proteins of SARS-CoV-2 in human volunteers, which to our knowledge has not been 400 reported before, and which is consistent with the fact that inactivated SARS-CoV-2 vaccines 401 present a plethora of antigens to the immune system that elicits antibodies against multiple 402 viral proteins. Notably, as viral variants with multiple mutations in the S protein continue to 403 emerge, it is of considerable importance the induction of polyclonal responses elicited by 404 inactivated vaccines that could help to avoid the viral escape [10]. These data complement 405 our previous findings that reported high titers of anti-S-RBD antibodies and neutralizing 406 antibodies against SARS-CoV-2 in phase III clinical trials on adult and pediatric volunteers 407 [9].

408 On the other hand, our results complement findings previously reported for the 409 SARS-CoV-2 inactivated virus vaccine BBIBP-CorV, where the authors showed that the N 410 protein, NSP7, and S2-78 peptide may be applied independently or in combination for 411 effective discrimination between individuals vaccinated with two doses and convalescents 412 subjects. However, individuals vaccinated with three doses or breakthrough cases were not 413 included, and M-specific IgG response was not investigated [42]. In another study, the 414 combined use of ORF3b and ORF8 showed to be accurate serological markers for detection 415 of early and late SARS-CoV-2 infection, but further studies evaluating their potential to 416 differentiate convalescent and vaccinated individuals at different time points after 417 vaccination and/or with different vaccines are missing [43]. Moreover, the specific properties 418 of the antibodies elicited after vaccination or natural infection, other than neutralization 419 capacity, should be considered in future studies to accurately identify a correlate of protection 420 against COVID-19 [36,37].

421 Overall, our results indicate that CoronaVac is immunogenic and that the host can 422 produce various antibodies against structural proteins of SARS-CoV-2. This could allow for 423 a potential differential diagnosis based on humoral immune components present in the sera 424 among subjects undergoing natural infection, vaccinated, or breakthrough cases. Moreover, our data show that immunization with an inactivated SARS-CoV-2 vaccine induces 425 426 significantly higher levels of antibodies against the structural protein M-SARS-CoV-2 427 compared to natural infection in unvaccinated subjects (convalescent subjects). Interestingly, 428 natural infection with SARS-CoV-2 elicits significantly higher titers of these antibodies 429 when the individuals were previously immunized (breakthrough cases) compared to 430 convalescent subjects. Additionally, we identified an antigen, ORF3a-SARS-CoV-2, against 431 which antibodies were produced in convalescent subjects at significantly higher titers than in 432 CoronaVac-immunized individuals.

Finally, it will be interesting to confirm the findings reported herein using high throughput analyses that consider a significant number of samples accompanied with the corresponding demographic information and details of the timing of the infection and severity of the reported symptoms for non-vaccinated convalescent individuals and breakthrough cases. Similarly, knowing the SARS-CoV-2 variant infecting the individuals could shed light onto potential differences regarding the immunogenicity of these viruses.

Taken together, our study reveals different SARS-CoV-2 antigens that could be used as differential biomarkers, alone or combined among them, for distinguishing between natural infection-, vaccination-elicited immune memory, or infection after vaccination. Here, we report that the structural M and N proteins are produced in a high percentage of vaccinated individuals along with high titers, which are further enhanced after a natural infection. These data could be helpful not only for serodiagnosis but also for evaluating vaccine efficacy

- through blood sample determination in the actual context in which SARS-CoV-2 infection is
- 446 highly prevalent worldwide.

447 FUNDING

448 PATH facilitated sera panels donations for this work. The work was also supported by the 449 Bill & Melinda Gates Foundation (https://www.gatesfoundation.org/) via grants INV-450 021239, and INV-016821. Under the grant conditions of the foundation, a Creative 451 Commons Attribution 4.0 generic License has already been assigned to the Author Accepted 452 Manuscript version that might arise from this submission. The funders did not have any 453 additional role in the study design, data collection and analysis, decision to publish, or 454 preparation of the manuscript. Laboratories providing samples used in this work: Microbial 455 Pathogenesis Laboratory and Molecular Biomedical Immunology Laboratory at FCB-UC 456 and accessed through the Washington Covid-19 Biorepository: The Everett Clinic and 457 Bloodworks Northwest. Scientific-clinical studies that generated serum samples evaluated in 458 this report (CoronaVac03CL) were supported by the Ministry of Health, Government of 459 Chile; The Confederation of Production and Commerce, Chile; the Consortium of 460 Universities for Vaccines and Therapies against COVID-19, Chile; the Chilean Public Health 461 Institute (ISP); the Millennium Institute on Immunology and Immunotherapy and Sinovac 462 Life Sciences Co. AMK, SMB and PAG are supported by the National Agency for Research 463 and Development (ANID) through the Fondo Nacional de Desarrollo Científico y 464 Tecnológico (FONDECYT) grants Nº1190830, Nº1170964, and Nº1190864, respectively. 465 The Millennium Institute on Immunology and Immunotherapy (ICN09 016/ICN 2021 045; 466 former P09/016-F) supports AMK, SMB and PAG; The Innovation Fund for 467 Competitiveness FIC-R 2017 (BIP Code: 30488811-0) supports AMK, SMB and PAG. BDV 468 is supported by ANID through the National Doctoral Scholarship, fellow #21221163. LFD 469 is supported by ANID through the Postdoctoral FONDECYT grant # 3210473.

470

471 ACKNOWLEDGMENTS

472 Special thanks to Rami Scharf, Miren Iturriza-Gomara and Jorge Flores from PATH for their 473 support on experimental design and discussion. We also thank the Vice Presidency of 474 Research (VRI), the Direction of Technology Transfer and Development (DTD), the Legal 475 Affairs Department (DAJ) of the Pontificia Universidad Católica de Chile. We are also 476 grateful to the Administrative Directions of the School of Biological Sciences (FCB) and the 477 School of Medicine (FMed) of the Pontificia Universidad Católica de Chile for their 478 administrative support.

REFERENCES

481		
482	1.	World Health Organization Global Excess Deaths Associated with COVID-19,
483		January 2020 - December 2021.
484	2.	Richards, F.; Kodjamanova, P.; Chen, X.; Li, N.; Atanasov, P.; Bennetts, L.;
485		Patterson, B.J.; Yektashenas, B.; Mesa-Frias, M.; Tronczynski, K.; et al.
486		Economic Burden of COVID-19: A Systematic Review. ClinicoEconomics and
487		Outcomes Research 2022, Volume 14, 293–307, doi:10.2147/CEOR.S338225.
488	3.	Krammer, F. A Correlate of Protection for SARS-CoV-2 Vaccines Is Urgently
489		Needed. Nature Medicine 2021, 27, 1147-1148, doi:10.1038/s41591-021-
490		01432-4.
491	4.	Nagy, A.; Alhatlani, B. An Overview of Current COVID-19 Vaccine Platforms.
492		Computational and Structural Biotechnology Journal 2021, 19, 2508–2517,
493		doi:10.1016/j.csbj.2021.04.061.
494	5.	Al-Jighefee, H.T.; Najjar, H.; Ahmed, M.N.; Oush, A.; Awwad, S.;
495		Kamareddine, L. COVID-19 Vaccine Platforms: Challenges and Safety
496		Contemplations. Vaccines (Basel) 2021, 9, 1196,
497		doi:10.3390/vaccines9101196.
498	6.	Ranzani, O.T.; Hitchings, M.D.T.; Dorion, M.; D'Agostini, T.L.; de Paula,
499		R.C.; de Paula, O.F.P.; Villela, E.F. de M.; Torres, M.S.S.; de Oliveira, S.B.;
500		Schulz, W.; et al. Effectiveness of the CoronaVac Vaccine in Older Adults
501		during a Gamma Variant Associated Epidemic of Covid-19 in Brazil: Test
502		Negative Case-Control Study. BMJ 2021, n2015, doi:10.1136/bmj.n2015.
503	7.	Zhang, Y.; Zeng, G.; Pan, H.; Li, C.; Hu, Y.; Chu, K.; Han, W.; Chen, Z.; Tang,
504		R.; Yin, W.; et al. Safety, Tolerability, and Immunogenicity of an Inactivated
505		SARS-CoV-2 Vaccine in Healthy Adults Aged 18–59 Years: A Randomised,
506		Double-Blind, Placebo-Controlled, Phase 1/2 Clinical Trial. The Lancet
507		Infectious Diseases 2021, 21, 181–192, doi:10.1016/S1473-3099(20)30843-4.
508	8.	Wu, Z.; Hu, Y.; Xu, M.; Chen, Z.; Yang, W.; Jiang, Z.; Li, M.; Jin, H.; Cui, G.;
509		Chen, P.; et al. Safety, Tolerability, and Immunogenicity of an Inactivated
510		SARS-CoV-2 Vaccine (CoronaVac) in Healthy Adults Aged 60 Years and
511		Older: A Randomised, Double-Blind, Placebo-Controlled, Phase 1/2 Clinical
512		Trial. The Lancet Infectious Diseases 2021, 21, 803-812, doi:10.1016/S1473-
513		3099(20)30987-7.
514	9.	Bueno, S.M.; Abarca, K.; González, P.A.; Gálvez, N.M.S.; Soto, J.A.; Duarte,
515		L.F.; Schultz, B.M.; Pacheco, G.A.; González, L.A.; Vázquez, Y.; et al. Safety
516		and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome
517		Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile. Clinical
518		Infectious Diseases 2021, doi:10.1093/cid/ciab823.
519	10.	Melo-González, F.; Soto, J.A.; González, L.A.; Fernández, J.; Duarte, L.F.;
520		Schultz, B.M.; Gálvez, N.M.S.; Pacheco, G.A.; Ríos, M.; Vázquez, Y.; et al.
521		Recognition of Variants of Concern by Antibodies and T Cells Induced by a
522		SARS-CoV-2 Inactivated Vaccine. Frontiers in Immunology 2021, 12,
523		doi:10.3389/fimmu.2021.747830.
524	11.	Jara, A.; Undurraga, E.A.; González, C.; Paredes, F.; Fontecilla, T.; Jara, G.;
525		Pizarro, A.; Acevedo, J.; Leo, K.; Leon, F.; et al. Effectiveness of an Inactivated

526		SARS-CoV-2 Vaccine in Chile. New England Journal of Medicine 2021, 385,
527		875–884, doi:10.1056/NEJMoa2107715.
528	12.	Ranzani, O.T.; Hitchings, M.D.T.; Dorion, M.; D'Agostini, T.L.; de Paula,
529		R.C.; de Paula, O.F.P.; Villela, E.F. de M.; Torres, M.S.S.; de Oliveira, S.B.;
530		Schulz, W.; et al. Effectiveness of the CoronaVac Vaccine in Older Adults
531		during a Gamma Variant Associated Epidemic of Covid-19 in Brazil: Test
532		Negative Case-Control Study. BMJ 2021, n2015, doi:10.1136/bmj.n2015.
533	13.	Duarte, L.F.; Gálvez, N.M.S.; Iturriaga, C.; Melo-González, F.; Soto, J.A.;
534		Schultz, B.M.; Urzúa, M.; González, L.A.; Vázquez, Y.; Ríos, M.; et al.
535		Immune Profile and Clinical Outcome of Breakthrough Cases After
536		Vaccination With an Inactivated SARS-CoV-2 Vaccine. Frontiers in
537		Immunology 2021, 12, doi:10.3389/fimmu.2021.742914.
538	14.	Tanriover, M.D.; Doğanay, H.L.; Akova, M.; Güner, H.R.; Azap, A.; Akhan,
539		S.; Köse, Ş.; Erdinç, F.Ş.; Akalın, E.H.; Tabak, Ö.F.; et al. Efficacy and Safety
540		of an Inactivated Whole-Virion SARS-CoV-2 Vaccine (CoronaVac): Interim
541		Results of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial in
542		Turkey. The Lancet 2021, 398, 213–222, doi:10.1016/S0140-6736(21)01429-
543		X.
544	15.	Alencar, C.H.; Cavalcanti, L.P. de G.; Almeida, M.M. de; Barbosa, P.P.L.;
545		Cavalcante, K.K. de S.; Melo, D.N. de; de Brito Alves, B.C.F.; Heukelbach, J.
546		High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related
547		Deaths in over 75-Year-Olds, Ceará State, Brazil. Tropical Medicine and
548		Infectious Disease 2021, 6, 129, doi:10.3390/tropicalmed6030129.
549	16.	Fiori, M.; Bello, G.; Wschebor, N.; Lecumberry, F.; Ferragut, A.; Mordecki, E.
550		Decoupling between SARS-CoV-2 Transmissibility and Population Mobility
551		Associated with Increasing Immunity from Vaccination and Infection in South
552		America. Scientific Reports 2022, 12, 6874, doi:10.1038/s41598-022-10896-4.
553	17.	Costa Clemens, S.A.; Weckx, L.; Clemens, R.; Almeida Mendes, A.V.; Ramos
554		Souza, A.; Silveira, M.B. v; da Guarda, S.N.F.; de Nobrega, M.M.; de Moraes
555		Pinto, M.I.; Gonzalez, I.G.S.; et al. Heterologous versus Homologous COVID-
556		19 Booster Vaccination in Previous Recipients of Two Doses of CoronaVac
557		COVID-19 Vaccine in Brazil (RHH-001): A Phase 4, Non-Inferiority, Single
558		Blind, Randomised Study. The Lancet 2022, 399, 521–529,
559		doi:10.1016/S0140-6736(22)00094-0.
560	18.	Farias, J.P.; da Silva, P. de S.; Fogaça, M.M.C.; Santana, I.V.R.; Luiz, W.B.;
561		Birbrair, A.; Amorim, J.H. The COVID-19 Humoral Immunological Status
562		Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from
563		a Booster Shot with the Pfizer Vaccine. Journal of Virology 2022,
564		doi:10.1128/jvi.00177-22.
565	19.	Jara, A.; Undurraga, E.A.; Zubizarreta, J.R.; González, C.; Pizarro, A.;
566		Acevedo, J.; Leo, K.; Paredes, F.; Bralic, T.; Vergara, V.; et al. Effectiveness
567		of Homologous and Heterologous Booster Doses for an Inactivated SARS-
568		CoV-2 Vaccine: A Large-Scale Prospective Cohort Study. The Lancet Global
569		Health 2022, 10, e798–e806, doi:10.1016/S2214-109X(22)00112-7.
570	20.	Tabilo Valenzuela, P.B.; Flores Balter, G.; Saint-Pierre Contreras, G.; Conei
571		Valencia, D.; Moreno Calderón, C.; Bohle Venegas, C.; Guajardo Rivera, M.;
572		Silva Ojeda, F.; Vial Covarrubias, M.J. Cellular Immune Response in Patients
		I

573		Immunized with Three Vaccine Doses of Different Vaccination Schemes
574		Authorized by the Chilean Ministry of Health in January 2022. Life 2022, 12,
575		534, doi:10.3390/life12040534.
576	21.	Redondo, N.; Zaldívar-López, S.; Garrido, J.J.; Montoya, M. SARS-CoV-2
577		Accessory Proteins in Viral Pathogenesis: Knowns and Unknowns. Frontiers
578		<i>in Immunology</i> 2021 , <i>12</i> , doi:10.3389/fimmu.2021.708264.
579	22.	Arya, R.; Kumari, S.; Pandey, B.; Mistry, H.; Bihani, S.C.; Das, A.; Prashar,
580		V.; Gupta, G.D.; Panicker, L.; Kumar, M. Structural Insights into SARS-CoV-
581		2 Proteins. Journal of Molecular Biology 2021, 433, 166725,
582		doi:10.1016/j.jmb.2020.11.024.
583	23.	Xia, X. Domains and Functions of Spike Protein in SARS-Cov-2 in the Context
584		of Vaccine Design. Viruses 2021, 13, 109, doi:10.3390/v13010109.
585	24.	Ke, Z.; Oton, J.; Qu, K.; Cortese, M.; Zila, V.; McKeane, L.; Nakane, T.;
586		Zivanov, J.; Neufeldt, C.J.; Cerikan, B.; et al. Structures and Distributions of
587		SARS-CoV-2 Spike Proteins on Intact Virions. Nature 2020, 588, 498-502,
588		doi:10.1038/s41586-020-2665-2.
589	25.	Romero Ramírez, D.S.; Lara Pérez, M.M.; Carretero Pérez, M.; Suárez
590		Hernández, M.I.; Martín Pulido, S.; Pera Villacampa, L.; Fernández Vilar,
591		A.M.; Rivero Falero, M.; González Carretero, P.; Reyes Millán, B.; et al.
592		SARS-CoV-2 Antibodies in Breast Milk After Vaccination. Pediatrics 2021,
593		148, doi:10.1542/peds.2021-052286.
594	26.	Barnes, C.O.; Jette, C.A.; Abernathy, M.E.; Dam, KM.A.; Esswein, S.R.;
595		Gristick, H.B.; Malyutin, A.G.; Sharaf, N.G.; Huey-Tubman, K.E.; Lee, Y.E.;
596		et al. SARS-CoV-2 Neutralizing Antibody Structures Inform Therapeutic
597		Strategies. Nature 2020, 588, 682–687, doi:10.1038/s41586-020-2852-1.
598	27.	Tea, F.; Ospina Stella, A.; Aggarwal, A.; Ross Darley, D.; Pilli, D.; Vitale, D.;
599		Merheb, V.; Lee, F.X.Z.; Cunningham, P.; Walker, G.J.; et al. SARS-CoV-2
600		Neutralizing Antibodies: Longevity, Breadth, and Evasion by Emerging Viral
601		Variants. <i>PLOS Medicine</i> 2021 , <i>18</i> , e1003656,
602		doi:10.1371/journal.pmed.1003656.
603	28.	World Health Organization WHO/BS.2020.2403 Establishment of the WHO
604		International Standard and Reference Panel for Anti-SARS-CoV-2 Antibody.
605	29.	Knezevic, I.; Mattiuzzo, G.; Page, M.; Minor, P.; Griffiths, E.; Nuebling, M.;
606		Moorthy, V. WHO International Standard for Evaluation of the Antibody
607		Response to COVID-19 Vaccines: Call for Urgent Action by the Scientific
608		Community. The Lancet Microbe 2022, 3, e235-e240, doi:10.1016/S2666-
609		5247(21)00266-4.
610	30.	Infantino, M.; Pieri, M.; Nuccetelli, M.; Grossi, V.; Lari, B.; Tomassetti, F.;
611		Calugi, G.; Pancani, S.; Benucci, M.; Casprini, P.; et al. The WHO International
612		Standard for COVID-19 Serological Tests: Towards Harmonization of Anti-
613		Spike Assays. International Immunopharmacology 2021, 100, 108095,
614		doi:10.1016/j.intimp.2021.108095.
615	31.	Kristiansen, P.A.; Page, M.; Bernasconi, V.; Mattiuzzo, G.; Dull, P.; Makar, K.;
616		Plotkin, S.; Knezevic, I. WHO International Standard for Anti-SARS-CoV-2
617		Immunoglobulin. The Lancet 2021, 397, 1347-1348, doi:10.1016/S0140-
618		6736(21)00527-4.

619	32.	Earle, K.A.; Ambrosino, D.M.; Fiore-Gartland, A.; Goldblatt, D.; Gilbert, P.B.;
620		Siber, G.R.; Dull, P.; Plotkin, S.A. Evidence for Antibody as a Protective
621		Correlate for COVID-19 Vaccines. Vaccine 2021, 39, 4423-4428,
622		doi:10.1016/j.vaccine.2021.05.063.
623	33.	Khoury, D.S.; Cromer, D.; Reynaldi, A.; Schlub, T.E.; Wheatley, A.K.; Juno,
624		J.A.; Subbarao, K.; Kent, S.J.; Triccas, J.A.; Davenport, M.P. Neutralizing
625		Antibody Levels Are Highly Predictive of Immune Protection from
626		Symptomatic SARS-CoV-2 Infection. Nature Medicine 2021, 27, 1205–1211,
627		doi:10.1038/s41591-021-01377-8.
628	34.	Sadarangani, M.; Marchant, A.; Kollmann, T.R. Immunological Mechanisms
629		of Vaccine-Induced Protection against COVID-19 in Humans. Nature Reviews
630		Immunology 2021 , 21, 475–484, doi:10.1038/s41577-021-00578-z.
631	35.	Bates, T.A.; McBride, S.K.; Leier, H.C.; Guzman, G.; Lyski, Z.L.; Schoen, D.;
632		Winders, B.; Lee, JY.; Lee, D.X.; Messer, W.B.; et al. Vaccination before or
633		after SARS-CoV-2 Infection Leads to Robust Humoral Response and
634		Antibodies That Effectively Neutralize Variants. Science Immunology 2022, 7,
635		doi:10.1126/sciimmunol.abn8014.
636	36.	Nordström, P.; Ballin, M.; Nordström, A. Risk of SARS-CoV-2 Reinfection
637		and COVID-19 Hospitalisation in Individuals with Natural and Hybrid
638		Immunity: A Retrospective, Total Population Cohort Study in Sweden. The
639		Lancet Infectious Diseases 2022, 22, 781-790, doi:10.1016/S1473-
640		3099(22)00143-8.
641	37.	Batra, M.; Tian, R.; Zhang, C.; Clarence, E.; Sacher, C.S.; Miranda, J.N.; de La
642		Fuente, J.R.O.; Mathew, M.; Green, D.; Patel, S.; et al. Role of IgG against N-
643		Protein of SARS-CoV2 in COVID19 Clinical Outcomes. Scientific Reports
644		2021 , <i>11</i> , 3455, doi:10.1038/s41598-021-83108-0.
645	38.	Nakayama, E.E.; Kubota-Koketsu, R.; Sasaki, T.; Suzuki, K.; Uno, K.;
646		Shimizu, J.; Okamoto, T.; Matsumoto, H.; Matsuura, H.; Hashimoto, S.; et al.
647		Anti-Nucleocapsid Antibodies Enhance the Production of IL-6 Induced by
648		SARS-CoV-2 N Protein. Scientific Reports 2022, 12, 8108,
649		doi:10.1038/s41598-022-12252-y.
650	39.	Kohler, P.; Güsewell, S.; Seneghini, M.; Egger, T.; Leal, O.; Brucher, A.;
651		Lemmenmeier, E.; Möller, J.C.; Rieder, P.; Ruetti, M.; et al. Impact of Baseline
652		SARS-CoV-2 Antibody Status on Syndromic Surveillance and the Risk of
653		Subsequent COVID-19-a Prospective Multicenter Cohort Study. BMC
654		Medicine 2021 , 19, 270, doi:10.1186/s12916-021-02144-9.
655	40.	Dugan, H.L.; Stamper, C.T.; Li, L.; Changrob, S.; Asby, N.W.; Halfmann, P.J.;
656		Zheng, NY.; Huang, M.; Shaw, D.G.; Cobb, M.S.; et al. Profiling B Cell
657		Immunodominance after SARS-CoV-2 Infection Reveals Antibody Evolution
658		to Non-Neutralizing Viral Targets. Immunity 2021, 54, 1290-1303.e7,
659		doi:10.1016/j.immuni.2021.05.001.
660	41.	Cheng, L.; Zhang, X.; Chen, Y.; Wang, D.; Zhang, D.; Yan, S.; Wang, H.; Xiao,
661		M.; Liang, T.; Li, H.; et al. Dynamic Landscape Mapping of Humoral Immunity
662		to SARS-CoV-2 Identifies Non-Structural Protein Antibodies Associated with
663		the Survival of Critical COVID-19 Patients. Signal Transduction and Targeted
664		<i>Therapy</i> 2021 , <i>6</i> , 304, doi:10.1038/s41392-021-00718-w.

- Ma, M.-L.; Shi, D.-W.; Li, Y.; Hong, W.; Lai, D.-Y.; Xue, J.-B.; Jiang, H.-W.;
 Zhang, H.-N.; Qi, H.; Meng, Q.-F.; et al. Systematic Profiling of SARS-CoV2-Specific IgG Responses Elicited by an Inactivated Virus Vaccine Identifies
 Peptides and Proteins for Predicting Vaccination Efficacy. *Cell Discovery*2021, 7, 67, doi:10.1038/s41421-021-00309-7.
- Hachim, A.; Kavian, N.; Cohen, C.A.; Chin, A.W.H.; Chu, D.K.W.; Mok,
 C.K.P.; Tsang, O.T.Y.; Yeung, Y.C.; Perera, R.A.P.M.; Poon, L.L.M.; et al.
 ORF8 and ORF3b Antibodies Are Accurate Serological Markers of Early and
 Late SARS-CoV-2 Infection. *Nature Immunology* 2020, *21*, 1293–1301,
 doi:10.1038/s41590-020-0773-7.

675

TABLES

Table 1.

Group	Time point evaluated	Gender	Age	Total
Vaccinated	Pre-immune	Female	18-59 years	12
	2nd dose + 2 weeks		> 60 years	4
	2nd dose + 4 weeks	Male	18-59 years	5
	Sru dose + 4 weeks		> 60 years	5
Convalescents	1 week 2 weeks 4 weeks 8 weeks	Unknown	Unknown	10
	Unspecified	Unknown	Unknown	9
Breakthrough	2 weeks	Female	18-59 years	3
	4 weeks		> 60 years	0
		Male	18-59 years	4
			> 60 years	3
Naïve	Before the year 2020	Unknown	Unknown	10

ANTIBODIES DETECTED	INDICATORS	2 ND DOSE + 4 WEEKS	3 RD DOSE + 4 WEEKS	BREAKTHROUGH + 4 WEEKS	CONVALESCENTS + 4 WEEKS	CONVALESCENTS UNSPECIFIED
	GMT	389.58	1433.96	11313.71	933.03	1080.06
Anti-N IgG	95% CI	197.27- 769.37	736.33 - 2792.54	3951.77 - 32390.55	438.27 - 1986.35	406.66 - 2868.58
	Seropositivity Rate (%)	44	88	100	90	89
	GMT	688.50	643.33	2939.47	168.24	170.10
Anti-M IgG	95% CI	298.68 - 1587.12	295.06 - 1402.67	734.28 - 11767.36	81.33 - 348.02	83.59 - 346.12
	Seropositivity Rate (%)	46	55	89	10	11
	GMT	232.03	224.49	174.11	125.99	174.11
Anti-E IgG	95% CI	151.12- 356.25	133.11 - 378.60	104.33 - 290.56	69.57 - 228.18	37.34 - 811.82
_	Seropositivity Rate (%)	43	33	40	29	20
	GMT	92.31	87.06	107.18	164.07	92.59
Anti-NSP8 IgG	95% CI	59.26 - 143.80	55.80 - 135.82	44.08, 260.61	48.85, 551.01	36.18, 236.97
	Seropositivity Rate (%)	27	24	30	57	22
	GMT	25.00	25.70	30.78	63.00	25.00
Anti-ORF3a	95% CI	25.00 - 25.00	24.27 - 27.22	19.23 - 49.27	22.45 - 176.77	25.00 - 25.00
igu	Seropositivity Rate (%)	0	5	10	50	0

Table 2. Seroconversion rates and geometric mean titers (GMTs) of antibodies against SARS-Cov-2 proteins

684 FIGURE AND FIGURE LEGENDS



Figure 1



Figure 1. Kinetics of specific anti-IgG levels against multiple structural and non-structural
SARS-CoV-2 proteins. A, B, and C. Serum samples from CoronaVac-vaccinated individuals
were obtained at the moment of the first dose (pre-immune), two and four weeks after the second

690	dose, and four weeks after a booster dose. D, E, and F. Convalescent individual serum sampling
691	was performed at 1, 2, 4, and 8 weeks after recovering from SARS-CoV-2 infection. Nine
692	convalescent individuals were evaluated without information about the time of sample collection
693	(Unspecified). G, H, and I. Follow-up samples from CoronaVac breakthrough cases (right) were
694	obtained two and four weeks after a positive PCR result. Serum from ten naïve individuals was
695	added as controls. Reciprocal antibody titers elicited against structural SARS-CoV-2 proteins (N,
696	M, and E) are shown in the upper panel. Reciprocal antibody titers elicited against non-structural
697	SARS-CoV-2 proteins (NSP8 and ORF3a) are shown in the middle panel. The seropositivity rates
698	were determined for each protein, and the respective time-points evaluated correspond to the lower
699	panels. Bars show the Geometric Mean Titer (GMT), and the error bars indicate 95% CI. A two-
700	way ANOVA test was used with Tukey's multiple comparison post-test. $*p < 0.05$, $**p < 0.01$,
701	*** $p < 0.001$, **** $p < 0.0001$.







Figure 2. Comparison of antibody levels between convalescent subjects and CoronaVacvaccinated individuals. Specific IgG antibodies titers in samples collected at four weeks after the second or booster dose in individuals belonging to the vaccinated group and four weeks after the diagnosis of SARS-CoV-2 infection by positive PCR result. Individuals from the breakthrough

708	group were compared with those from the convalescent group (samples obtained four weeks after
709	the recovery from SARS-CoV-2 infection and individuals for whom there is no data regarding
710	when the samples were collected). A, B, and C. Reciprocal antibody titers against N, M, and E-
711	specific IgG. D and E. Reciprocal IgG specific antibody titers against NSP-8 and ORF3a. The
712	numbers above the groups show the Geometric Mean Titer (GMT), and the error bars indicate the
713	95% CI. The numbers in red indicate the fold decrease. The blue text indicates fold increases. A
714	Kruskal-Wallis test was used with Dunn's multiple comparison post-test, $*p < 0.05$, $**p < 0.01$,
715	***p < 0.001. F and G. ROC analyses of IgG responses to the N (violet), M (yellow), E (blue),
716	NSP-8 (green), and ORF3a (pink) proteins to compare vaccinated individuals after the
717	administration of two or three doses of CoronaVac and convalescent subjects, respectively. Ara
718	under the curve (AUC) values are indicated in parenthesis.

Figure 3



Figure 3. ROC analyses of IgG responses to structural and non-structural SARS-CoV proteins for comparing CoronaVac breakthrough cases with vaccinated individuals and
 convalescent individuals. ROC curves were constructed to identify SARS-CoV-2 proteins that
 can differentiate breakthrough cases from A. individuals that received two doses of CoronaVac.
 B. individuals receiving three doses (two in the primary schedule, plus one booster) of CoronaVac

726 C. Convalescent individuals. Sera collected four weeks after recovery from infection, vaccination, 727 and breakthrough cases were analyzed. For the convalescent group, nine individuals with an 728 unspecified time of sample collection were included. D, E, and F. AUC values, negative predictive 729 power, and positive predictive power for the combinations of M and N antibodies titers to 730 differentiate the breakthrough cases from **D**. individuals that received two doses of CoronaVac. **E**. 731 individuals that received three doses of CoronaVac F. Convalescent individuals. G, H and I. 732 Scatter plots distributions along with cutoff values for IgG responses based on optimal Youden values related to ROC curves: convalescent individuals (light blue), individuals vaccinated with 733 734 two (dark blue), or three (green) doses, and breakthrough cases (orange).

736 737 SUPPLEMENTARY TABLES AND FIGURES

Supplementary Table 1. Geometric mean units (GMU) of antibodies against SARS-CoV-2 proteins

ANTIBODIES DETECTED	INDICATORS	2 ND DOSE + 4 WEEKS	3 RD DOSE + 4 WEEKS	BREAKTHROUGH +4 WEEKS	CONVALESCENTS + 4 WEEKS	CONVALESCENTS UNSPECIFIED INFECTION TIME
	GMU	79.1	197.2	1224.0	127.0	116.7
Anti-N igo	95% CI	41.75- 150.2	96.7 - 402.1	495.4 - 3026	67.84 - 237.7	50.74 - 268.2
	GMU	246.1	163.9	586.0	51.26	31.9
Anti- M IgG	95% CI	136.3 - 444.2	94.75 -283.4	234.1 - 1467	27.53 - 95.46	15.92 - 63.89
Anti-NSP8	GMU	15.5	14.68	20.5	20.66	23.62
lgG	95% CI	13.2- 18.31	13.0- 16.57	10.4- 40.4	12.5- 34.11	10.0- 55.59

739 Figure S1



Supplementary Figure 2



760 Figure S2. IgG level kinetics against structural and non-structural SARS-CoV-2 proteins 761 expressed as WHO-binding antibody units (BAU). Serum samples from CoronaVac-vaccinated 762 individuals were obtained at the first dose (pre-immune), two and four weeks after the second dose, 763 and four weeks after a booster dose for evaluating A. N-specific IgG antibodies, B. M-specific IgG 764 antibodies, C. NSP8-specific IgG antibodies. Serum sampling of convalescent individuals was 765 performed at 1, 2, 4, and 8 weeks after recovery from SARS-CoV-2 infection. Nine convalescent 766 individuals without information regarding the time of sample collection (Unspecified) were included for evaluating, D. N-specific IgG antibodies, E. M-specific IgG antibodies, F. NSP8-767

768	specific IgG antibodies. Follow-up samples from breakthrough cases were obtained two and four
769	weeks after a positive PCR result for evaluating G. N-specific IgG antibodies, H. M-specific IgG
770	antibodies, and I. NSP8-specific IgG antibodies. Sera from ten naïve individuals were added as
771	controls. Bars show the Geometric Mean Units (GMU), and the error bars indicate 95% CI. A
772	Kruskal-Wallis test was used with Dunn's multiple comparison post-test, $*p < 0.05$, $**p < 0.01$,
773	*** $p < 0.001$, **** $p < 0.0001$.